GRI Bio, Inc.
GRI
Rank in Stocks
#31107
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The companyโs portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Share Price
$1.71
Last synced: 2026-11-09
Market Cap
$3.74M
Change (1 day)
-9.04%
Change (1 year)
-96.70%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade GRI Bio, Inc. (GRI)
Category
Healthcare
EPS for GRI Bio, Inc. (GRI)
EPS as of June 2026 TTM: $-43.70
According to GRI Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-43.70. At the end of 2025 the company had an EPS of $-121.80, a decrease compared to its 2024 EPS of $0.33.
EPS history for GRI Bio, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-43.70 | -64.12% |
| 2025 | $-121.80 | -37,009.09% |
| 2024 | $0.33 | -100.00% |
| 2023 | $-140.45K | 197.97% |
| 2022 | $-47.14K | 1,567.24% |
| 2021 | $-2.83K | -39.77% |
| 2020 | $-4.69K | -99.29% |
| 2019 | $-660.97K | -19.67% |
| 2018 | $-822.78K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -135.84% |
US
|
|
| $-7.07 | -83.82% |
US
|
|
| $-5.29 | -87.89% |
AU
|
|
| $12.88 | -129.47% |
BE
|
|
| $21.56 | -149.34% |
NL
|
Questions about GRI Bio, Inc.'s earnings per share (EPS)
What is GRI Bio, Inc.'s earnings per share (EPS)?
GRI Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-43.70, as of Jun 2026.
What was GRI Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, GRI Bio, Inc.'s earnings per share (EPS) was $-121.80, compared with $0.33 in 2024.
How has GRI Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, GRI Bio, Inc.'s earnings per share (EPS) was highest in 2024 ($0.33) and lowest in 2023 ($-140.45K).
How does GRI Bio, Inc.'s earnings per share (EPS) compare with similar companies?
GRI Bio, Inc.'s earnings per share (EPS) ($-43.70) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.